Allurion Gastric Balloon System
Allurion Technologies, Inc. · Decision date Sep 23, 2026
What did the FDA approve?
The FDA database entry records an approval decision, dated 2026-09-23, for supplement P250023/S002 to PMA P250023, the Allurion Gastric Balloon System. The supplement type is the Normal 180 Day Track No User Fee, and the stated reason is a postapproval study protocol. The applicant is Allurion Technologies, Inc. The device falls under product code LTI in the category implant, intragastric for morbid obesity, within Gastroenterology, Urology.
The source statement identifies the changed item as the revised protocol for the post-approval study Allurion Gastric Balloon PAS. The announcement of the revised protocol does not by itself establish safety or clinical effectiveness of the device. The entry does not describe protocol content, study endpoints, patient numbers, or trial results; those details are absent from the supplied fields. It does not grant a new approval of the whole system.
FDA approval order statement
the revised protocol for the post-approval study (PAS) Allurion Gastric Balloon PAS
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 23, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250023/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Allurion Technologies, Inc.
- Product code
- LTI
- Decision code
- APPR
- Decision date
- Sep 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.
- Applicant
- Allurion Technologies, Inc.
- Product code
- LTI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250023 · Original PMA
Allurion Gastric Balloon System
P250023/S002 received
Application receipt date recorded by FDA.
P250023/S001 · Related supplement
Allurion Gastric Balloon System
P250023/S002 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Allurion Technologies, Inc. | PMA approval | Feb 20, 2026 | FDA | |
Allurion Gastric Balloon SystemP250023/S001 | Allurion Technologies, Inc. | PMA supplement | Sep 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allurion Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 11 Huron Dr., Natick, MA, 01760
Sources and methodology
- Original FDA record: P250023/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
